https://www.selleckchem.com/pr....oducts/defactinib.ht
In the subsequent survival analysis, the OS and LCSS rates of adjuvant therapy patients showed a significant survival advantage over those treated with sublobectomy alone (P0.05). The survival analysis was performed again after propensity match scoring, generating similar results (P0.05). There was still a significant difference in OS between adjuvant therapy and lobectomy alone (P0.05). Chemoradiotherapy can improve the OS of patients with NSCLC ≤3 cm after sublobectomy and reduce death caused by tumors. Therefore, when
Like
Comment
Share
